Optimizing Survival Benefit by Surgical Resection by the Seven-Eleven Criteria in Barcelona Clinic Liver Cancer Stage A/B Hepatocellular Carcinoma beyond the Milan Criteria.

"Conflict of Interest Statement T.-H.S. received research grant from Gilead Sciences and was on speaker's bureaus for AbbVie, Bayer, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Takeda. J.-H.K. has served as a consultant for AbbVie, Gilead Sciences, Merck Sharp and Dohme, and Roche and on speaker's bureaus for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp, and Dohme. Others declare no conflict of interests."

"This work was supported by grants from the Ministry of Science and Technology, Taiwan (Grant No. MOST 109-2326-B-002-012-MY3, MOST 110-2326-B-400-004, MOST 110-2628-B-002-041), Ministry of Health and Welfare (Grant No. MOHW111-TDU-B-221-114003), National Taiwan University Hospital (Grant No. VN-111-07, 111-T20), and the Liver Disease Prevention & Treatment Research Foundation, Taiwan."